EP
AXSM icon

Essential Partners’s Axsome Therapeutics AXSM Stock Holding History

Essential Partners’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25K Sell
102
-90
-47% -$19.5K 0.01% 826
2026
Q1 		$32.5K Hold
192
– – 0.01% 742
2025
Q4 		$35.1K Hold
192
– – 0.01% 710
2025
Q3 		$23.3K Sell
192
-24
-11% -$2.7K 0.01% 840
2025
Q2 		$22.5K Buy
+216
New +$22.9K 0.01% 641

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Essential Partners's AXSM Position: Q2 2026 in Review

Essential Partners reduced its Axsome Therapeutics (AXSM) stake by 47% in Q2 2026, selling an estimated $19.5K and leaving 102 shares worth $25K. The position accounts for 0.01% of the portfolio, ranked #826.

Essential Partners first reported a position in AXSM in Q2 2025 and has held it in 5 quarters since. The position peaked at $35.1K in Q4 2025. 505 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Essential Partners held 102 shares of Axsome Therapeutics worth $25K as of Q2 2026.
  • Essential Partners sold 90 Axsome Therapeutics shares in Q2 2026, an estimated $19.5K.
  • Axsome Therapeutics made up 0.01% of Essential Partners's portfolio in Q2 2026, its #826 holding.
  • Essential Partners first reported a position in Axsome Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's Axsome Therapeutics position peaked at $35.1K in Q4 2025.
  • 505 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.